{"id":"tmc435-hpmc-capsule","_chembl":{"chemblId":"CHEMBL501849","moleculeType":"Small molecule","molecularWeight":"749.96"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"HCV NS3/4A protease","explanation":"TMC435 is a direct-acting antiviral that selectively binds to and inhibits the NS3/4A serine protease of hepatitis C virus. This protease is essential for cleaving the HCV polyprotein into functional viral proteins. By blocking this enzyme, TMC435 prevents viral replication and reduces viral load in infected patients.","oneSentence":"TMC435 inhibits the HCV NS3/4A serine protease, blocking viral polyprotein processing and preventing hepatitis C virus replication."},"_scrapedAt":"2026-03-28T06:28:45.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123037,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"telaprevir","brand":"Incivek","company":"Vertex Pharmaceuticals","rationale":"HCV NS3/4A protease inhibitor for hepatitis C treatment"},{"name":"boceprevir","brand":"Victrelis","company":"Merck","rationale":"HCV NS3/4A protease inhibitor for hepatitis C treatment"},{"name":"danoprevir","brand":null,"company":"Roche","rationale":"Investigational HCV protease inhibitor in development"}],"description":"TMC435 HPMC capsule is an investigational antiviral agent developed by Tibotec Pharmaceuticals for the treatment of hepatitis C virus (HCV) infection. As a protease inhibitor, it targets the HCV NS3/4A serine protease, which is essential for viral replication. The compound was evaluated in early-stage clinical trials.","indications":{"approved":[{"status":"investigational","condition":"Hepatitis C virus infection","patientPopulation":"Adult patients, investigational"}]},"trialDetails":[{"nctId":"NCT01308606","phase":"PHASE1","title":"TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"TMC435 HPMC capsule","genericName":"TMC435 HPMC capsule","companyName":"Tibotec Pharmaceuticals, Ireland","companyId":"tibotec-pharmaceuticals-ireland","firstApprovalDate":"","aiSummary":"TMC435 HPMC capsule is a small molecule used to treat Hepatitis C. It is administered in the form of a capsule, with HPMC (hydroxypropyl methylcellulose) as a component.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}